Gout.

BMJ clinical evidence Pub Date : 2015-03-19
Martin Underwood
{"title":"Gout.","authors":"Martin Underwood","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Gout affects about 5% of men and 1% of women, with up to 80% of people experiencing a recurrent attack within 3 years.</p><p><strong>Methods and outcomes: </strong>We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of treatments for acute gout? What are the effects of xanthine oxidase inhibitors to prevent gout in people with prior acute episodes? We searched: Medline, Embase, The Cochrane Library, and other important databases up to September 2013 (Clinical Evidence reviews are updated periodically; please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).</p><p><strong>Results: </strong>We found 21 studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.</p><p><strong>Conclusions: </strong>In this systematic review, we present information relating to the effectiveness and safety of the following interventions: colchicine, corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs), and xanthine oxidase inhibitors.</p>","PeriodicalId":72432,"journal":{"name":"BMJ clinical evidence","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2015-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4365763/pdf/2015-1120.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMJ clinical evidence","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Gout affects about 5% of men and 1% of women, with up to 80% of people experiencing a recurrent attack within 3 years.

Methods and outcomes: We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of treatments for acute gout? What are the effects of xanthine oxidase inhibitors to prevent gout in people with prior acute episodes? We searched: Medline, Embase, The Cochrane Library, and other important databases up to September 2013 (Clinical Evidence reviews are updated periodically; please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).

Results: We found 21 studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.

Conclusions: In this systematic review, we present information relating to the effectiveness and safety of the following interventions: colchicine, corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs), and xanthine oxidase inhibitors.

痛风。
引言:痛风影响约5%的男性和1%的女性,高达80%的人在3年内复发。方法和结果:我们进行了一项系统综述,旨在回答以下临床问题:急性痛风的治疗效果如何?黄嘌呤氧化酶抑制剂对既往有急性发作的人预防痛风有什么作用?截至2013年9月,我们搜索了:Medline、Embase、The Cochrane Library和其他重要数据库(临床证据审查定期更新;请查看我们的网站以获取此审查的最新版本)。我们纳入了美国食品药品监督管理局(FDA)和英国药品和医疗保健产品监管局(MHRA)等相关组织的危害警报。结果:我们发现21项研究符合我们的纳入标准。我们对干预措施的证据质量进行了GRADE评估。结论:在这篇系统综述中,我们提供了以下干预措施的有效性和安全性相关信息:秋水仙碱、皮质类固醇、非甾体抗炎药(NSAIDs)和黄嘌呤氧化酶抑制剂。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信